Review Article

Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications

Table 2

Applications of ctDNA quantification and monitoring for melanoma patients. PBL: peripheral blood lymphocytes.

GeneSampleApplicationReferences

BRAFSerum(i) Tumor response monitoring
(ii) Prognostic value
[17]

BRAFSerum/plasmaAdvanced stage IV monitoring[9]

BRAFSerumIdentification of genetic determinants for targeted therapy[3]

BRAFPlasmaIdentification of genetic determinants for targeted therapy[21]

BRAFSerum/plasmaIdentification of genetic determinants for targeted therapy[19]

BRAFPlasmaIdentification of genetic determinants for targeted therapy[36]

BRAFPBL(i) Identification of genetic determinants for targeted therapy
(ii) Evaluation of early treatment response
(iii) Monitoring of minimal residual disease
[22]

GNAQ
GNA11
PlasmaPrognostic value[26]

BRAFPlasma(i) Identification of genetic determinants for targeted therapy
(ii) Monitoring of tumor dynamics
(iii) Prognostic value
[28]

BRAF
NRAS
TERT
 Promoter
PlasmaEvaluation of early treatment response to immunotherapy[33]

BRAFPlasma/serum(i) Prognostic value
(ii) Monitoring of tumor dynamics
(iii) Evaluation of early treatment response
(iv) Monitoring of minimal residual disease
[18]

BRAFPlasmaPrognostic value[32]

BRAF
NRAS
Plasma(i) Monitoring of tumor dynamics
(ii) Monitoring of minimal residual disease
(iii) Real-time assessment of resistance
[30]

BRAFPlasmaPrognostic value[34]

BRAFPlasma(i) Prognostic value
(ii) Monitoring of tumor dynamics
(iii) Evaluation of early treatment response
(iv) Real-time assessment of resistance
[34]

BRAF
NRAS
Plasma(i) Prognostic value
(ii) Evaluation of early treatment response
(iii) Real-time assessment of resistance
[30]

BRAFPlasma(i) Identification of genetic determinants for targeted therapy
(ii) Prognostic value
[20]

ExomePlasma(i) Evaluation of early treatment response
(ii) Real-time assessment of resistance
[35]